NEPHROGENIC ANEMIA: AN INDIVIDUAL APPROACH TO ITS TREATMENT
- Authors: Ryasnyansky V.1, Shostka G.1
-
Affiliations:
- I.I. Mechnikov Northwestern State Medical Academy
- Issue: Vol 23, No 6 (2012)
- Pages: 23-26
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115426
- ID: 115426
Cite item
Open Access
Access granted
Abstract
The treatment of nephrogenic anemia may be unsafe, clearly manifesting itself when large-dose erythropoietic stimulants are used. In this case it is particularly important to estimate the expected benefits and risks of the therapy in a specific patient and the possibilities of reducing the dose of stimulants.
Keywords
Full Text
About the authors
V. Ryasnyansky
I.I. Mechnikov Northwestern State Medical Academy
Email: ryasn2006@rambler.ru
Associate Professor, Candidate of Medical Sciences Saint Petersburg
G. Shostka
I.I. Mechnikov Northwestern State Medical AcademyProfessor, MD Saint Petersburg
References
- Varat M., Adolph R., Fowler N. Cardiovascular effects of anemia // Am. Heart. J. - 1972; 83 (3): 415-26.
- Hertig A., Ferrer-Marin F. Correction of anaemia on dialysis: did we forget physiology? // Nephrol. Dial. Transplant. - 2011; 26 (4): 1120-2.
- McFarlane P., Pisoni R., Eichleay M., Wald R., Port F. Mendelssohn D International trends in erythropoietin use and hemoglobin levels in hemodialysis patients // Kidney Int. - 2010; 78: 215-23.
- Besarab A., Bolton W., Browne J. et al. The effects of normal as compared with low hematocrit values in patients with Med. - 1998; 339: 584-90.
- Drueke T., Locatelli F., Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia // N. Engl. J. Med. - 2006; 355: 2071-84.
- Singh A., Sczcech L., Tang K. et al. Correction of anemia with epoetin alfa in chronic kidney disease // N. Engl. J. Med. - 2006; 355: 2085-98.
- Pfeffer M., Burdmann E., Chen C. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease // N. Engl. J. Med. - 2009; 362: 2019-32.
- Kainz A., Mayer B., Kramar R., Oberbauer R. Association of ESA hyporesponsiveness and haemoglobin variability with mortality in haemodialysis patients // Nephrol. Dial. Transplant. - 2010; 25: 3701-6.
- Bonafont X., Bock A., Carter D et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis // NDT Plus. -2009; 2 (5): 347-53.
- Bock A., Hirt-Minkowski P, Brünisholz M. et al. Swiss EFIXNES trial investigators Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/ beta // Nephrol. Dial. Transplant. - 2008; 23: 301-8.
Supplementary files
